EUSA Pharma announce acquisition of SYLVANT® from Janssen
Pharmafield (press release)
SYLVANT® is approved in more than 40 countries worldwide, including the United States, the European Union, the Republic of Korea and Canada, for the treatment of idiopathic multicentric Castleman's disease (iMCD), a rare, life threatening and

X